Bio-Techne Corporation (TECH)

Over the past six months, Bio-Techne's stock has increased by 28.47%. In Q1 CY2025, the company met revenue expectations and beat EPS estimates, with organic revenue rising year-on-year. In Q2 CY2025, Bio-Techne again topped revenue expectations and beat EPS estimates, with organic revenue also increasing. The company has launched new products and partnerships, including advancements in its spatial biology portfolio. The stock has faced uncertainty due to funding environment concerns for biopharmaceuticals and biotech research, but there are encouraging signs of stabilization. Bio-Techne announced a new share repurchase program authorizing up to $500 million of common stock.

Information explicitly detailing demand seasonality for Bio-Techne Corp.'s products and services was not found. The company's core reagents and instruments business has historically experienced mid to high single-digit growth, driven by ongoing innovation in drug discovery and development. The emerging cell and gene therapy business is projected to sustain a +20% growth rate, indicating consistent demand. Macroeconomic challenges and biotech funding environments can impact demand, but these are generally market-wide factors rather than inherent seasonality.

Bio-Techne Corp. is a life sciences company focused on developing, manufacturing, and selling reagents, instruments, and services for research, diagnostic, and bioprocessing markets. The company operates through two segments: Protein Sciences and Diagnostics and Spatial Biology, providing tools and reagents for scientific investigations, disease progression, drug discovery, and clinical testing. Its major products and services include reagents like ELISA kits and antibodies, instruments such as automated protein analysis tools and spatial biology platforms, diagnostic products like controls and assays, and custom services including antibody and gene engineering services.

Bio-Techne has a global presence with its headquarters in Minneapolis, Minnesota, USA, and employs over 3,000 people across 34 locations worldwide. Approximately 55% of its net sales are from the United States, 20% from Europe/Middle East/Africa (EMEA), 5% from the UK, and 15% from Asia-Pacific (APAC), with the remaining 5% from other regions. It specifically operates in the UK, the US, and China.

Bio-Techne maintains a strong brand reputation due to its history and focus on high-quality reagents, instruments, and services. The company is recognized as a leader in manufacturing high-quality antibodies and proteins used in life sciences research. Continuous innovation through new product launches, strategic partnerships and collaborations, and consistent financial performance have positively reinforced its reputation. No specific negative events significantly impacting Bio-Techne's brand reputation were identified.

Institutional investors hold a significant majority of Bio-Techne Corp.'s stock, with approximately 86.14% held by institutions and about 1.08% by individuals. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., Price T Rowe Associates Inc /md/, Morgan Stanley, State Street Corp, T. Rowe Price New Horizons Fund, Inc., and Geode Capital Management, Llc.